source
- Molecular Partners to cut up to 44% of staff as it shifts focus to radiotherapy pipelineMolecular Partners announced it will lay off up to 44% of its workforce, affecting as many as 55 positions, as the Swiss biotech redirects its limited cash toward a radiotherapeutic program. The c…
- AstraZeneca drops two early-phase prostate cancer programsAstraZeneca announced it is terminating development of two early-phase prostate cancer candidates, AZD9750 and AZD8359, as part of a quarterly pipeline review. AZD9750, an oral androgen-receptor d…